EPRX Eupraxia Pharmaceuticals Inc
- 3.670
- +0.130+3.67%
Eupraxia Pharmaceuticals Inc News
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
VICTORIA, BC, July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diff
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. al
Eupraxia Pharmaceuticals Announces Voting Results From Annual General and Special Meeting of Shareholders
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data From the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
07:02 AM EDT, 06/05/2024 (MT Newswires) -- Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheu
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%
Eupraxia Pharmaceuticals Inc. (EPRX.TO and NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with signi
Eupraxia Pharmaceuticals to Present Initial Results From Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Press Release: Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Canada NewsWire VICTORIA, BC, May 8, 2024 -- Eupraxia common shares now listed on the Nasdaq C
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
Stocks in Play: Eupraxia Pharmaceuticals Inc.\
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
VICTORIA, BC, April 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary D
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
Eupraxia Pharmaceuticals Inc Price Target Cut to C$16.50/Share From C$19.00 by Raymond James
Eupraxia Pharmaceuticals Inc Price Target Cut to C$16.50/Share From C$19.00 by Raymond James
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company"
Canadian Investment Regulatory Organization Trade Resumption - EPRX
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company"
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company"
Canadian Investment Regulatory Organization Trading Halt - EPRX
